# US 2012/0252045 A1 · Method of assessing islet function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252045 A1
- Document ID: US20120252045A1
- Status: Published application
- Kind: A1
- Application number: 13/393,587
- Filed: 2010-09-03
- Published: 2012-10-04
- Earliest claimed: 2009-09-03
- Inventors: Andrew Pepper
- Web page: https://patentgrep.com/patent/US20120252045A1

## CPC

- G01N 33/507: {Pancreatic cells}
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 2800/245: Transplantation related diseases, e.g. graft versus host disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for assessing islet function comprising determining an oxygen consumption rate (OCR) of the islets; determining an islet index (II) of the islets; and determining an OCR/II ratio, wherein a high OCR/II ratio correlates with increased islet function. The methods may be performed on islets in vitro. In some embodiments, the methods may be performed on islets to be used for transplantation after they are harvested from a donor pancreas and prior to transplanting the islets into a recipient.

## Claims

### Claim 1

A method of assessing islet cell function, comprising:
determining an oxygen consumption rate (OCR) of a group of islet cells;
determining an islet index (II) of the islet cells; and
determining an OCR/II ratio, wherein a high OCR/II ratio correlates with improved islet function in vivo.

### Claim 2 (depends on 1)

The method of claim 1, further comprising determining whether or not the islets are suitable for implantation in a host based on the OCR/II ratio.

### Claim 3 (depends on 1)

The method of claim 1, wherein the host is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein the host is a non-human animal.

### Claim 5 (depends on 1)

The method of claim 1, wherein islets having an OCR/II ratio within a range of about 50 nmol/min-mg DNA to about 250 nmol/min-mgDNA are identified as being suitable for transplantation.

### Claim 6 (depends on 1)

The method of claim 1, wherein islets having an OCR/II ratio of about 50, 60, 70, 80, 90 nmol/min-mg DNA or more are identified as being suitable for transplantation.

### Claim at position 7

7-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the OCR/II ratio is determined by dividing the number of islet equivalents (IEQ) in a sample by the actual number of islets in the sample.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method is performed prior to transplanting islets into a recipient.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein islet function is measured as the ability of the islets to reverse diabetes in a diabetic recipient of an islet transplant and/or as increased probability of the ability of the islet to reverse diabetes in a diabetic recipient of an islet transplant.

### Claim 15 (depends on 14)

The method of claim 14, wherein reversal of diabetes comprises production of at least one of a non-fasting blood glucose below 11.1 mmol/L or a fasting blood glucose 7.8 mmol/L post transplant.

### Claim 16 (depends on 1)

The method of claim 1, wherein islet function is measured as the ability of an islet transplant to improve blood glucose levels in a diabetic recipient of an islet transplant.

### Claim 17 (depends on 16)

The method of claim 16, wherein improved blood glucose comprises at least one of: a reduction in Hemoglobin A1C (HbA1C) compared to pre-transplant values; an increase in serum C-peptide concentrations compared to pre-transplant values; an improved response to a glucose tolerance test as measured by area under curve for glucose; insulin; and c-peptide; and glucose disappearance rates.

### Claim at position 15

18-19. (canceled)

### Claim 20 (depends on 14)

The method of claim 14, wherein the probability that an islet transplant will reverse diabetes post-transplant is given by the equation: Pr(reversal)=1 over (1+exp(2.4030−0.033 Index).

### Claim 21 (depends on 1)

The method of claim 1, wherein determining an OCR of a group of islet cells comprises placing the islets in an area having a known oxygen concentration and measuring the change in oxygen concentration over time.

### Claim 22 (depends on 1)

The method of claim 1, wherein the islets comprise at least one of human islets, non-human animal islets, stem cells, genetically modified cells, or any cell which releases insulin.

### Claim 23 (depends on 1)

The method of claim 1, wherein the islets comprise porcine islets.

### Claim 24 (depends on 1)

The method of claim 1, wherein the islets are adult islets.

### Claim at position 21

25-35. (canceled)

### Claim 36 (depends on 1)

The method of claim 1, wherein the portion of the group of islet, cells comprises 2,000 IEQ or fewer.

### Claim at position 23

37-39. (canceled)

### Claim 40

A device for assessing islet cell function, comprising:
a first cell analysis unit configured to determine an oxygen consumption rate (OCR) of a group of islet cells;
a second cell analysis unit configured to determine an islet index (II) of the islet cells; and
a computation unit configured to determine an OCR/II ratio, wherein a high OCR/II ratio correlates with improved islet function in vivo.

### Claim 41 (depends on 40)

The device of claim 40, wherein the first cell analysis unit comprises an oxygen sensor.
